VentriPoint Diagnostics Announces Change To The Board Of Directors And Opening Of Manufacturing Facility In Canada
SEATTLE, WASHINGTON--(Marketwired - Feb 15, 2016) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE:VPT) is pleased to announce that Dr. Don Segal has joined the Board of Directors of the Company replacing Mr. Treuman Katz, who has stepped down after 8 years as a Director of the Company.
"It has been a great privilege to work with Treuman, who has been the thoughtful, strategic and considerate Chairman of the Board for all my time at Ventripoint," stated Dr. George Adams, President and CEO. "We at Ventripoint wish him all the best."
"I am pleased to welcome Dr. Segal to the Board of Directors and I look forward to his advice as the Company continues to commercialize the VMS™ technology for analysis of the whole heart."
Dr. Segal is an entrepreneur with a successful history starting companies both in the private and public sector. With approximately 40 years of experience in the healthcare industry, he has managed several start-up companies through to commercialization. He is currently the Chairman and CEO of United Biopharmaceuticals Inc. Previously he founded Joldon Diagnostics and spearheaded its amalgamation with Intercon Pharma and Helix Biotech to form Helix BioPharma Corp, where he was Chairman and CEO. During his tenure, the company was listed on the TSX and NYSE and raised significant funding from capital markets to support product development. Dr. Segal's first company was Radioimmunoassay Inc. (RIA Inc), which was sold as a private company. Dr. Segal has a Ph.D. in Medical Sciences from the University of Guelph.
In other news, Ventripoint has established a development and manufacturing facility in Toronto, Canada. This will also serve as the head office of the Company. The facility will undergo an ISO certification audit in April. The Company's new office phone number will be 416-848-4156 and fax number 416-848-0709.
The Company also announces that it has granted 37,500 Deferred Share Units (DSU's) to certain directors. Under the terms of the Company's DSU plan, holders of DSUs may redeem each DSU for one share of common stock upon the termination of their services to the Company, at no cost to the holder.
"It has been a great privilege to work with Treuman, who has been the thoughtful, strategic and considerate Chairman of the Board for all my time at Ventripoint," stated Dr. George Adams, President and CEO. "We at Ventripoint wish him all the best."
"I am pleased to welcome Dr. Segal to the Board of Directors and I look forward to his advice as the Company continues to commercialize the VMS™ technology for analysis of the whole heart."
Dr. Segal is an entrepreneur with a successful history starting companies both in the private and public sector. With approximately 40 years of experience in the healthcare industry, he has managed several start-up companies through to commercialization. He is currently the Chairman and CEO of United Biopharmaceuticals Inc. Previously he founded Joldon Diagnostics and spearheaded its amalgamation with Intercon Pharma and Helix Biotech to form Helix BioPharma Corp, where he was Chairman and CEO. During his tenure, the company was listed on the TSX and NYSE and raised significant funding from capital markets to support product development. Dr. Segal's first company was Radioimmunoassay Inc. (RIA Inc), which was sold as a private company. Dr. Segal has a Ph.D. in Medical Sciences from the University of Guelph.
In other news, Ventripoint has established a development and manufacturing facility in Toronto, Canada. This will also serve as the head office of the Company. The facility will undergo an ISO certification audit in April. The Company's new office phone number will be 416-848-4156 and fax number 416-848-0709.
The Company also announces that it has granted 37,500 Deferred Share Units (DSU's) to certain directors. Under the terms of the Company's DSU plan, holders of DSUs may redeem each DSU for one share of common stock upon the termination of their services to the Company, at no cost to the holder.